A vaccine for HIV being developed by the Norwegian vaccine company Bionor Pharma could soon be a reality as researchers have found that median HIV viral load reduction more than doubled among participants with high anti-C5/gp41732-744 antibody levels given the Vacc-4x vaccine. Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. If confirmed, the biomarker may be able to predict which patients will benefit most from the therapeutic HIV vaccine candidate Vacc-4x.
No comments:
Post a Comment